PCR Journal Club

Coronary microvascular dysfunction is increasingly recognised as a key determinant of outcomes beyond epicardial coronary disease. The FLOW-CMD registry provides new insights into its prevalence and prognostic impact in routine invasive practice.

The study aimed to evaluate the impact of LAAC device implantation depth on local flow characteristics and its association with device-related thrombus using patient-specific computational fluid dynamics.

Catheter-based left atrial appendage closure (LAAC) is widely used as an alternative to oral anticoagulation in atrial fibrillation. But how does it compare with best medical therapy in patients at high risk of both stroke and bleeding? The CLOSURE-AF trial provides new data to inform this...

The review aims to address the unmet needs in heart failure (HF) management, particularly in patients where structural heart disease coexists with HF and limits the effectiveness of guideline-directed medical therapy (GDMT).

The aim of this study was to comprehensively assess the prognostic impact of TAPSE/PASP and its longitudinal variation in AS patients undergoing TAVR.

This is the largest real world observational data that confirms the safety and efficacy of TAVR for the treatment of patients with severe aortic stenosis presenting with cardiogenic shock. 

The results of PREDICT-LAA remain fascinating and point focus on a current topic such as the use of AI models in planning structural cardiac interventions.

The OPTIMUM study evaluates the outcomes in patients with complex CAD, including significant LM disease, its equivalent, or MVD CAD, undergoing percutaneous revascularization in addition to guideline directed medical therapy (GDMT) versus GDMT alone.

Pediatric patients requiring anticoagulation are a rare but extremely complex subgroup, with congenital (univentricular circulation, Fontan circulation, venous-to-systemic shunts) or acquired diseases (Kawasaki disease), which represents a therapeutic and logistic challenge.

Wollmuth et al in the RESTORE EF study sought to examine the impact of Impella assisted HRPCI on LV function at 90-day follow-up.